{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-041591","form_type":"8-K","ticker":"NUWE","cik":"0001506492","company_name":"Nuwellis, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.582953+00:00","generated_at":"2026-05-16T21:06:33.858328+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuwellis Q3 revenue $2.2M, down 6% YoY, up 29% sequentially; operating loss widens to $2.7M","bullets":["Total revenue $2.2M, down 6% YoY but up 29% sequentially; pro-forma revenue grew ~7% YoY excluding one-time items.","Gross margin 65.2% (down from 70% YoY); operating loss $2.7M vs $1.5M last year.","Cash $3.1M at quarter end, debt-free; raised $1.9M via ATM facility.","Launched new 24-hour circuit and dual-lumen catheter; first hospital-based outpatient therapies under new CMS code.","Pediatric Vivian system accelerated with NIH funding; manufacturing transition to KDI Precision initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-041591","json":"https://secwatch.observer/filing/0001140361-25-041591.json","markdown":"https://secwatch.observer/filing/0001140361-25-041591.md","text":"https://secwatch.observer/filing/0001140361-25-041591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/0001140361-25-041591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/ef20058643_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:06:33.858328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}